• Publications
  • Influence
Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.
The HER-2/neu oncogene is a member of the erbB-like oncogene family, and is related to, but distinct from, the epidermal growth factor receptor. This gene has been shown to be amplified in humanExpand
Erlotinib in previously treated non-small-cell lung cancer.
BACKGROUND We conducted a randomized, placebo-controlled, double-blind trial to determine whether the epidermal growth factor receptor inhibitor erlotinib prolongs survival in non-small-cell lungExpand
Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group.
PURPOSE Patients with advanced pancreatic cancer have a poor prognosis and there have been no improvements in survival since the introduction of gemcitabine in 1996. Pancreatic tumors oftenExpand
Infiltrating lobular carcinoma of the breast: tumor characteristics and clinical outcome
IntroductionInvasive lobular carcinoma (ILC) comprises approximately 10% of breast cancers and appears to have a distinct biology. Because it is less common than infiltrating ductal carcinoma (IDC),Expand
Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer.
PURPOSE Immunohistochemistry (IHC) is a newer technique for assessing the estrogen receptor (ER) status of breast cancers, with the potential to overcome many of the shortcomings associated with theExpand
Prognostic and predictive factors in breast cancer by immunohistochemical analysis.
Most recent decisions for breast cancer patients are made on the basis of prognostic and predictive factors. In addition to the traditional tumor/nodal/metastasis staging variables, estrogen andExpand
Revision of the American Joint Committee on Cancer staging system for breast cancer.
PURPOSE To revise the American Joint Committee on Cancer staging system for breast carcinoma. MATERIALS AND METHODS A Breast Task Force submitted recommended changes and additions to the existingExpand
Reporting recommendations for tumor marker prognostic studies (REMARK).
Despite years of research and hundreds of reports on tumor markers in oncology, the number of markers that have emerged as clinically useful is pitifully small. Often, initially reported studies of aExpand
Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer.
BACKGROUND AIB1 (SRC-3) is an estrogen receptor (ER) coactivator that, when overexpressed in cultured cells, can reduce the antagonist activity of tamoxifen-bound ERs. Signaling through the HER-2Expand
Tumor characteristics and clinical outcome of elderly women with breast cancer.
BACKGROUND The number of elderly patients with breast cancer is increasing. Limited age-related information available about this disease prompted this study. PATIENTS AND METHODS The studyExpand